725247-18-7
XCT 790
CAS: 725247-18-7
Molecular Formula: C23H13F9N4O3S
725247-18-7 - Names and Identifiers
725247-18-7 - Physico-chemical Properties
| Molecular Formula | C23H13F9N4O3S |
| Molar Mass | 596.42 |
| Solubility | DMSO: ≥10mg/mL |
| Appearance | solid |
| Color | yellow |
| Storage Condition | 2-8°C |
| Use | XCT-790 is a potent selective inverse agonist of ERRα with an IC50 value of 0.37 μM. XCT-790 induces cancer cell death during chemotherapy. XCT-790 was inactive against ERRγ and estrogen receptors ERα and ERβ. |
725247-18-7 - Risk and Safety
| WGK Germany | 3 |
725247-18-7 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.677 ml | 8.383 ml | 16.766 ml |
| 5 mM | 0.335 ml | 1.677 ml | 3.353 ml |
| 10 mM | 0.168 ml | 0.838 ml | 1.677 ml |
| 5 mM | 0.034 ml | 0.168 ml | 0.335 ml |
Last Update：2024-01-02 23:10:35
725247-18-7 - Introduction
XCT 790 is a chemical compound that belongs to a class of drugs called selective estrogen receptor modulators. It has some of the following properties:
1. Selectivity: XCT 790 regulates the activity of the receptor by binding to the estrogen receptor and preventing the effect of estrogen on the receptor. It acts primarily on the estrogen receptor alpha (ERα) and has a lesser effect on the estrogen receptor beta (ERβ).
2. Purpose: XCT 790 is used to study the effect of estrogen receptor on hormone-dependent cancers (such as breast cancer, endometrial cancer, etc.), and to provide theoretical basis for the development of new drugs for the treatment of such cancers.
3. Preparation method: the preparation method of XCT 790 is generally obtained by organic synthesis. There are many specific methods for preparing the compound, but generally involve a multi-step synthesis and purification process.
4. Safety information: Information on the safety and toxicity of XCT 790 is currently relatively limited because it is mainly used for research purposes and not as a drug. However, it should be noted that, as with other compounds, the use or handling of XCT 790 requires appropriate laboratory safety measures and compliance with relevant chemical storage, handling and use regulations. In addition, further toxicity studies are necessary for this class of pharmaceutical compounds in order to evaluate their safety in future clinical applications.
1. Selectivity: XCT 790 regulates the activity of the receptor by binding to the estrogen receptor and preventing the effect of estrogen on the receptor. It acts primarily on the estrogen receptor alpha (ERα) and has a lesser effect on the estrogen receptor beta (ERβ).
2. Purpose: XCT 790 is used to study the effect of estrogen receptor on hormone-dependent cancers (such as breast cancer, endometrial cancer, etc.), and to provide theoretical basis for the development of new drugs for the treatment of such cancers.
3. Preparation method: the preparation method of XCT 790 is generally obtained by organic synthesis. There are many specific methods for preparing the compound, but generally involve a multi-step synthesis and purification process.
4. Safety information: Information on the safety and toxicity of XCT 790 is currently relatively limited because it is mainly used for research purposes and not as a drug. However, it should be noted that, as with other compounds, the use or handling of XCT 790 requires appropriate laboratory safety measures and compliance with relevant chemical storage, handling and use regulations. In addition, further toxicity studies are necessary for this class of pharmaceutical compounds in order to evaluate their safety in future clinical applications.
Last Update：2024-04-09 19:04:59
Supplier List
Spot supply
Product Name: XCT 790 Visit Supplier Webpage Request for quotationCAS: 725247-18-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: XCT 790 Visit Supplier Webpage Request for quotationCAS: 725247-18-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History